| 17.37 -0.31 (-1.75%) | 04-19 11:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.4  |
1-year : | 26.82 |
| Resists | First : | 20.89 |
Second : | 22.96 |
| Pivot price | 19.92 |
|||
| Supports | First : | 17.54 |
Second : | 14.59 |
| MAs | MA(5) : | 18.54 |
MA(20) : | 20.21 |
| MA(100) : | 17.53  |
MA(250) : | 13.21 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 7 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 24.17 | Low : | 7.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KURA ] has closed above bottom band by 0.3%. Bollinger Bands are 17.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.92 - 19.05 | 19.05 - 19.15 |
| Low: | 17.55 - 17.73 | 17.73 - 17.86 |
| Close: | 17.75 - 17.98 | 17.98 - 18.17 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Fri, 19 Apr 2024
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year? - Yahoo Canada Shine On
Mon, 15 Apr 2024
StockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
Mon, 15 Apr 2024
Kura Oncology, Inc. (NASDAQ:KURA) Shares Purchased by DekaBank Deutsche Girozentrale - MarketBeat
Wed, 10 Apr 2024
Kura Oncology to Participate in Stifel Targeted Oncology Forum - Investing.com Nigeria
Tue, 26 Mar 2024
Should You Buy Kura Oncology Inc (KURA) Stock on Tuesday? - InvestorsObserver
Sun, 10 Mar 2024
Cantor sees strong year ahead for oncology M&A (NASDAQ:KURA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 105.5 (%) |
| Shares Short | 10,410 (K) |
| Shares Short P.Month | 11,020 (K) |
| EPS | -2.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -37.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -125 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -8.5 |
| PEG Ratio | -0.5 |
| Price to Book value | 3.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|